Orthodox Baháʼí Faith (Remey line)
A living tradition within Baháʼí Faith. The disagreements in the sources are shown rather than settled.
Orthodox Baháʼí Faith (Remey line) is a living tradition within Baháʼí Faith. Also written Orthodox Baháʼís Under the Hereditary Guardianship, Baháʼís under the Hereditary Guardianship.
Origin
Founder named in the sources: Charles Mason Remey (1874–1974). Founding date given as 1960. In 1960 Charles Mason Remey, a Hand of the Cause, declared himself the second Guardian, arguing that the Guardianship was an essential and continuing part of the Baháʼí Covenant and resting his claim on his appointment as president of the International Baháʼí Council. From a base in Florence he appointed local spiritual assemblies in Santa Fe (New Mexico), Rawalpindi (Pakistan) and Lucknow (India), and organised the election of two national assemblies in 1963, in the United States and Pakistan. His followers splintered into rival lines even before his death.
Continue reading this article
Sign in free to read in full. Become a member to join the discussion without limits.
Sign in free to read- ✓Read every article
- ✓Comment and reply (up to 100 words, 10/month)
- ✓Browse the community
- ✓Reader badge
Citation
English
The language and the date you read it belong in the citation: this corpus is multilingual and articles are revised after publication.
John Shaqi. “Orthodox Baháʼí Faith (Remey line).” English version. 11 August 2026. https://johnshaqi.com/articles/sect-orthodox-baha-i-faith-remey-line.
@misc{johnshaqi-sect-orthodox-baha-i-faith-remey-line-en,
author = {John Shaqi},
title = {Orthodox Baháʼí Faith (Remey line)},
year = {2026},
howpublished = {English version},
url = {https://johnshaqi.com/articles/sect-orthodox-baha-i-faith-remey-line},
note = {Accessed n.d.}
}The word count is counted from this edition. The minute estimate uses 238 words a minute, the silent reading rate for English non-fiction reported by Brysbaert (2019). The Urdu, Hindi and Roman Urdu editions carry a word count and no estimate, because no comparable rate has been published for those scripts.